HK1202538A1 - Heterocyclyl compounds as mek inhibitors mek - Google Patents

Heterocyclyl compounds as mek inhibitors mek

Info

Publication number: HK1202538A1
Authority: HK; Hong Kong
Prior art keywords: mek; heterocyclyl compounds; inhibitors; heterocyclyl; compounds
Prior art date: 2012-03-14

Application number

HK15103051.3A

Other languages

English (en)

Chinese (zh)

Inventor

Bhavesh Dave

Rakesh Kumar Banerjee

Samiron Phukan

Abhijit Datta Khoje

Rajkumar Hangarge

Jitendra Sambhaji Jadhav

Venkata P Palle

Rajender Kumar Kamboj

Original Assignee

Lupin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-14

Filing date

2015-03-25

Publication date

2015-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-25 Application filed by Lupin Ltd filed Critical Lupin Ltd

2015-10-02 Publication of HK1202538A1 publication Critical patent/HK1202538A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)

HK15103051.3A 2012-03-14 2015-03-25 Heterocyclyl compounds as mek inhibitors mek HK1202538A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN288KO2012		2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors

Publications (1)

Publication Number	Publication Date
HK1202538A1 true HK1202538A1 (en)	2015-10-02

Family

ID=47997632

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK15103051.3A HK1202538A1 (en)	2012-03-14	2015-03-25	Heterocyclyl compounds as mek inhibitors mek
HK15106571.7A HK1206020A1 (en)	2012-03-14	2015-07-09	Heterocyclyl compounds

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK15106571.7A HK1206020A1 (en)	2012-03-14	2015-07-09	Heterocyclyl compounds

Country Status (36)

Country	Link
US (5)	US9573944B2 (xx)
EP (2)	EP2834236B1 (xx)
JP (3)	JP6431770B2 (xx)
KR (4)	KR102241111B1 (xx)
CN (4)	CN107698585A (xx)
AP (2)	AP3859A (xx)
AU (4)	AU2013234009B2 (xx)
BR (1)	BR112014022713B1 (xx)
CA (2)	CA2865167C (xx)
CL (2)	CL2014002412A1 (xx)
CO (2)	CO7170131A2 (xx)
CR (2)	CR20140463A (xx)
CU (2)	CU24335B1 (xx)
DK (2)	DK2834236T3 (xx)
DO (2)	DOP2014000203A (xx)
EA (2)	EA028232B1 (xx)
ES (2)	ES2741896T3 (xx)
GE (2)	GEP201706671B (xx)
GT (2)	GT201400196A (xx)
HK (2)	HK1202538A1 (xx)
IL (2)	IL234559A (xx)
IN (2)	IN2014MN01755A (xx)
MA (2)	MA37405A1 (xx)
MX (3)	MX355526B (xx)
MY (2)	MY174188A (xx)
NI (2)	NI201400107A (xx)
NZ (2)	NZ629432A (xx)
PE (2)	PE20141973A1 (xx)
PH (2)	PH12014502041A1 (xx)
PL (1)	PL2834237T3 (xx)
SG (2)	SG11201405006PA (xx)
TN (2)	TN2014000356A1 (xx)
TR (1)	TR201811976T4 (xx)
UA (2)	UA114907C2 (xx)
WO (2)	WO2013136249A1 (xx)
ZA (1)	ZA201406186B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR102241111B1 (ko)	2012-03-14	2021-04-15	루핀 리미티드	Ｍｅｋ 억제제로서 헤테로사이클릴 화합물
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
WO2014172644A2 (en)	2013-04-19	2014-10-23	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
BR112016007396B1 (pt)	2013-10-25	2021-01-19	Shanghai Hengrui Pharmaceutical Co., Ltd.	Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica
WO2016009306A1 (en) *	2014-07-15	2016-01-21	Lupin Limited	Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) *	2014-09-04	2016-03-10	Lupin Limited	Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es)	2015-02-20	2022-02-22	Incyte Corp	Heterociclos bicíclicos como inhibidores de FGFR
CN110167928A (zh)	2016-12-22	2019-08-23	勃林格殷格翰国际有限公司	作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202005881YA (en) *	2017-12-21	2020-07-29	Boehringer Ingelheim Int	Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019213506A1 (en)	2018-05-04	2019-11-07	Incyte Corporation	Salts of an fgfr inhibitor
PL3788047T3 (pl)	2018-05-04	2025-04-14	Incyte Corporation	Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
KR20210142154A (ko)	2019-03-21	2021-11-24	옹쎄오	암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114375202A (zh)	2019-06-19	2022-04-19	勃林格殷格翰国际有限公司	抗癌组合疗法
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
BR112022001678A2 (pt) *	2019-07-30	2022-05-03	Edvince Ab	Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (de)	2019-09-27	2021-03-31	Primetals Technologies Austria GmbH	Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja)	2019-10-14	2022-12-15	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
IL293001A (en)	2019-12-04	2022-07-01	Incyte Corp	Derivatives of an fgfr inhibitor
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CA3183656A1 (en) *	2020-06-02	2021-12-09	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
US20240238294A1 (en)	2021-04-09	2024-07-18	Boehringer Ingelheim International Gmbh	Anticancer therapy
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4323066A1 (en) *	2021-04-16	2024-02-21	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
EP4441050A1 (en)	2021-12-01	2024-10-09	Boehringer Ingelheim International GmbH	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
AU2022402390A1 (en)	2021-12-01	2024-05-30	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en)	2021-12-01	2024-10-09	Boehringer Ingelheim International GmbH	Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
US20250129096A1 (en)	2021-12-01	2025-04-24	Boehringer Ingelheim Int'l GmbH Corp.	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337432A (zh)	2021-12-01	2023-10-01	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114605408B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) *	2022-03-30	2023-09-01	沈阳药科大学	5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
US20250019385A1 (en)	2023-05-30	2025-01-16	Boehringer Ingelheim International Gmbh	Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
UA72612C2 (en) *	2000-07-06	2005-03-15		Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) *	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
GB0129099D0 (en)	2001-12-05	2002-01-23	Astrazeneca Ab	Chemical compounds
OA12755A (en) *	2002-01-22	2006-07-03	Warner Lambert Co	2-(pyridin-2-ylamino)-pyridoÄ2,3dÜpyrimidin-7-ones.
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004293018B2 (en)	2003-11-19	2010-02-18	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
PT1761528E (pt) *	2004-06-11	2008-04-15	Japan Tobacco Inc	Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
AU2009344690A1 (en)	2009-04-21	2011-10-27	Novartis Ag	Heterocyclic compounds as MEK inhibitors
KR102241111B1 (ko) *	2012-03-14	2021-04-15	루핀 리미티드	Ｍｅｋ 억제제로서 헤테로사이클릴 화합물

2013
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en active Application Filing
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en active Application Filing
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
2014
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
2015
- 2015-03-25 HK HK15103051.3A patent/HK1202538A1/xx unknown
- 2015-07-09 HK HK15106571.7A patent/HK1206020A1/xx not_active IP Right Cessation
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active

Also Published As

Publication number	Publication date
IN2014MN01754A (xx)	2015-07-03
DOP2014000203A (es)	2015-02-15
MX355526B (es)	2018-04-20
MY175950A (en)	2020-07-16
TN2014000356A1 (en)	2015-12-21
MX366426B (es)	2019-07-08
EP2834236A1 (en)	2015-02-11
EA028232B1 (ru)	2017-10-31
PL2834237T3 (pl)	2018-11-30
EP2834237A1 (en)	2015-02-11
JP6431770B2 (ja)	2018-11-28
SG11201405006PA (en)	2014-10-30
WO2013136249A1 (en)	2013-09-19
SG11201405007QA (en)	2014-10-30
HK1206020A1 (en)	2015-12-31
CU24335B1 (es)	2018-04-03
CU20140110A7 (es)	2014-11-27
CO7170131A2 (es)	2015-01-28
CN108383836A (zh)	2018-08-10
CA2865164A1 (en)	2013-09-19
US20170101408A1 (en)	2017-04-13
NZ629442A (en)	2016-12-23
JP6630771B2 (ja)	2020-01-15
NI201400108A (es)	2014-11-28
GT201400196A (es)	2017-09-28
MA37400B1 (fr)	2019-11-29
PH12014502041B1 (en)	2014-11-24
US9573944B2 (en)	2017-02-21
CU20140109A7 (es)	2014-11-27
GEP201706671B (en)	2017-05-25
AU2017200493A1 (en)	2017-02-16
MX2014010928A (es)	2015-04-10
IL234560A (en)	2017-06-29
BR112014022713B1 (pt)	2021-09-08
EA201491671A1 (ru)	2014-12-30
US20150299186A1 (en)	2015-10-22
PE20141973A1 (es)	2014-12-12
MX355474B (es)	2018-04-16
CA2865167A1 (en)	2013-09-19
EP2834236B1 (en)	2019-05-22
PH12014502040A1 (en)	2014-11-24
AU2013234009A1 (en)	2014-09-25
WO2013136254A1 (en)	2013-09-19
PE20141974A1 (es)	2014-12-12
UA114907C2 (uk)	2017-08-28
ES2741896T3 (es)	2020-02-12
KR20140138911A (ko)	2014-12-04
CA2865164C (en)	2021-06-08
MA37405A1 (fr)	2016-03-31
KR102241111B1 (ko)	2021-04-15
MX2014010925A (es)	2015-04-10
JP2015514056A (ja)	2015-05-18
PH12014502041A1 (en)	2014-11-24
BR112014022713A2 (xx)	2017-06-20
CL2014002411A1 (es)	2015-04-06
DK2834236T3 (da)	2019-08-26
CR20140464A (es)	2014-11-28
CR20140463A (es)	2014-11-28
IL234559A (en)	2017-06-29
MA37400A1 (fr)	2016-05-31
US20170112840A1 (en)	2017-04-27
UA114906C2 (uk)	2017-08-28
GT201400195A (es)	2017-11-09
US20160331753A1 (en)	2016-11-17
US9428499B2 (en)	2016-08-30
CN104203947A (zh)	2014-12-10
AU2013234014A1 (en)	2014-09-25
KR102240101B1 (ko)	2021-04-14
CU24272B1 (es)	2017-08-08
GEP201706774B (en)	2017-11-27
TR201811976T4 (tr)	2018-09-21
AP3859A (en)	2016-10-31
JP6093384B2 (ja)	2017-03-08
AU2013234014B2 (en)	2017-02-02
AU2018202568A1 (en)	2018-05-10
IN2014MN01755A (xx)	2015-07-03
ZA201406186B (en)	2016-06-29
EP2834237B1 (en)	2018-06-06
US9969731B2 (en)	2018-05-15
KR20190100472A (ko)	2019-08-28
CL2014002412A1 (es)	2015-03-06
AP2014008009A0 (en)	2014-10-31
KR20190073597A (ko)	2019-06-26
DOP2014000204A (es)	2015-02-15
NI201400107A (es)	2014-11-26
JP2015509975A (ja)	2015-04-02
JP2018115215A (ja)	2018-07-26
US9555035B2 (en)	2017-01-31
PH12014502040B1 (en)	2014-11-24
AP3834A (en)	2016-09-30
EA201491672A1 (ru)	2014-12-30
AU2013234009B2 (en)	2016-10-27
CA2865167C (en)	2019-08-06
AU2018202568B2 (en)	2019-05-09
AP2014008008A0 (en)	2014-10-31
ES2684517T3 (es)	2018-10-03
US9827247B2 (en)	2017-11-28
DK2834237T3 (en)	2018-08-27
CN107698585A (zh)	2018-02-16
TN2014000357A1 (en)	2015-12-21
CN104271577A (zh)	2015-01-07
US20150133424A1 (en)	2015-05-14
NZ629432A (en)	2017-01-27
EA029768B1 (ru)	2018-05-31
MY174188A (en)	2020-03-12
CN108383836B (zh)	2021-11-12
KR20140138910A (ko)	2014-12-04
AU2017200493B2 (en)	2018-03-29
CO7160029A2 (es)	2015-01-15

Publication	Publication Date	Title
AP3859A (en)	2016-10-31	Heterocyclyl compounds as MEK inhibitors
HK1211921A1 (en)	2016-06-03	Inhibitor compounds
HK1201200A1 (en)	2015-08-28	Substituted pyrrolidine-2-carboxamides -2-
HK1197063A1 (en)	2015-01-02	Heterocyclyl aminoimidazopyridazines
HK1208442A1 (en)	2016-03-04	Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1200830A1 (en)	2015-08-14	Substituted pyrrolidine-2-carboxamides -2-
HK1207366A1 (en)	2016-01-29	Thiadiazolidinediones as gsk-3 inhibitors gsk-3
HK1206724A1 (en)	2016-01-15	Substituted benzothienopyrimidines
HK1210178A1 (en)	2016-04-15	Substituted pyridopyrazines as syk inhibitors syk
GB201202368D0 (en)	2012-03-28	Tracking method
GB201214842D0 (en)	2012-10-03	Content tracker
HK1209422A1 (en)	2016-04-01	Fbxo3 inhibitors fbxo3
EP2934541A4 (en)	2016-08-03	NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh)	2015-12-31	取代的咪唑並噠嗪
GB201211019D0 (en)	2012-08-01	Inhibitor compounds
EP2929742A4 (en)	2015-12-23	TRACKING DEVICE